<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties manuscript?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">9111860</journal-id><journal-id journal-id-type="pubmed-jr-id">20952</journal-id><journal-id journal-id-type="nlm-ta">Int J Antimicrob Agents</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Antimicrob. Agents</journal-id><journal-title-group><journal-title>International journal of antimicrobial agents</journal-title></journal-title-group><issn pub-type="ppub">0924-8579</issn><issn pub-type="epub">1872-7913</issn></journal-meta><article-meta><article-id pub-id-type="pmid">28232214</article-id><article-id pub-id-type="pmc">6934037</article-id><article-id pub-id-type="doi">10.1016/j.ijantimicag.2017.02.003</article-id><article-id pub-id-type="manuscript">HHSPA1062774</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Reduced susceptibility to cefixime but not ceftriaxone: an uncertain
perspective for the treatment of gonorrhoea in Brazil</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Costa-Louren&#x000e7;o</surname><given-names>Ana Paula Ramalho</given-names></name><aff id="A1">Institute of Microbiology, Federal University of Rio de Janeiro,
Avenida Carlos Chagas Filho 373, CCS, Bloco I, Laborat&#x000f3;rio I2-59,
Cidade Universit&#x000e1;ria, Rio de Janeiro, RJ 21941-902, Brazil</aff></contrib><contrib contrib-type="author"><name><surname>Abrams</surname><given-names>Jeanine A.</given-names></name><aff id="A2">National Center for HIV/AIDS, Viral Hepatitis, STD, and TB
Prevention, US Centers for Disease Control and Prevention, 1600 Clifton
Road, Atlanta, GA 30329-4027, USA</aff></contrib><contrib contrib-type="author"><name><surname>Barros dos Santos</surname><given-names>K&#x000e9;sia Tha&#x000ed;s</given-names></name><aff id="A3">Institute of Microbiology, Federal University of Rio de Janeiro,
Avenida Carlos Chagas Filho 373, CCS, Bloco I, Laborat&#x000f3;rio I2-59,
Cidade Universit&#x000e1;ria, Rio de Janeiro, RJ 21941-902, Brazil</aff></contrib><contrib contrib-type="author"><name><surname>Coelho-Souza</surname><given-names>Talita</given-names></name><aff id="A4">National Institute of Healthy Quality Control,
Funda&#x000e7;&#x000e3;o Oswaldo Cruz, Av. Brasil 4365, Manguinhos, Rio de
Janeiro, RJ CEP 21040-900, Brazil</aff></contrib><contrib contrib-type="author"><name><surname>Moreira</surname><given-names>Beatriz Meurer</given-names></name><aff id="A5">Institute of Microbiology, Federal University of Rio de Janeiro,
Avenida Carlos Chagas Filho 373, CCS, Bloco I, Laborat&#x000f3;rio I2-59,
Cidade Universit&#x000e1;ria, Rio de Janeiro, RJ 21941-902, Brazil</aff></contrib><contrib contrib-type="author"><name><surname>Fracalanzza</surname><given-names>Sergio Eduardo Longo</given-names></name><aff id="A6">Institute of Microbiology, Federal University of Rio de Janeiro,
Avenida Carlos Chagas Filho 373, CCS, Bloco I, Laborat&#x000f3;rio I2-59,
Cidade Universit&#x000e1;ria, Rio de Janeiro, RJ 21941-902, Brazil</aff></contrib><contrib contrib-type="author"><name><surname>Trees</surname><given-names>David L.</given-names></name><aff id="A7">National Center for HIV/AIDS, Viral Hepatitis, STD, and TB
Prevention, US Centers for Disease Control and Prevention, 1600 Clifton
Road, Atlanta, GA 30329-4027, USA</aff></contrib><contrib contrib-type="author"><name><surname>Bonelli</surname><given-names>Raquel Regina</given-names></name><xref rid="CR1" ref-type="corresp">*</xref><aff id="A8">Institute of Microbiology, Federal University of Rio de Janeiro,
Avenida Carlos Chagas Filho 373, CCS, Bloco I, Laborat&#x000f3;rio I2-59,
Cidade Universit&#x000e1;ria, Rio de Janeiro, RJ 21941-902, Brazil</aff></contrib></contrib-group><author-notes><corresp id="CR1"><label>*</label>Corresponding author. Institute of Microbiology,
Federal University of Rio de Janeiro, Avenida Carlos Chagas Filho 373, CCS,
Bloco I, Laborat&#x000f3;rio I2-59, Cidade Universit&#x000e1;ria, Rio de Janeiro,
RJ 21941-902, Brazil. Fax: +55 21 2560 8344.
<email>raquel.bonelli@micro.ufrj.br</email> (R.R. Bonelli)</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>11</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>21</day><month>2</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>12</month><year>2019</year></pub-date><volume>49</volume><issue>4</issue><fpage>515</fpage><lpage>516</lpage><!--elocation-id from pubmed: 10.1016/j.ijantimicag.2017.02.003--></article-meta></front><body><p id="P20">Sir,</p><p id="P1">Resistance to extended-spectrum cephalosporins (ESC) in <italic>Neisseria
gonorrhoeae</italic> has been described in different countries and is an important
cause for concern regarding the successful treatment of gonorrhoea [<xref rid="R1" ref-type="bibr">1</xref>]. Modifications of the penicillin-binding protein 2
<italic>(penA)</italic> gene are the main ESC resistance determinants in gonococcus
[<xref rid="R2" ref-type="bibr">2</xref>]. Specific mosaic <italic>penA</italic>
alleles are associated with cefixime minimum inhibitory concentrations (MICs) equivalent
to the Clinical and Laboratory Standards Institute (CLSI) susceptibility breakpoint for
cefixime (MIC &#x02264; 0.25 mg/L), which characterises reduced susceptibility to
cefixime (Cef<sup>RS</sup>) [<xref rid="R3" ref-type="bibr">3</xref>]. Thus, despite no
longer being recommended as a first-line treatment for gonococcal infections (<ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/std/tg2015/gonorrhea.htm">http://www.cdc.gov/std/tg2015/gonorrhea.htm</ext-link>),
cefixime is considered a sentinel drug associated with the evolution of ESC resistance
in <italic>N. gonorrhoeae</italic> [<xref rid="R3" ref-type="bibr">3</xref>]. Additional
mutations in mosaic alleles, including A501P in <italic>penA</italic> XXXIV, and A311V,
T316P and T483S in <italic>penA</italic> X, lead to high-level ESC resistance [<xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R4" ref-type="bibr">4</xref>].</p><p id="P2">Brazil currently recommends ciprofloxacin combined with azithromycin for
gonorrhoea therapy in the vast majority of its territory, excluding some states where
ciprofloxacin should be replaced with ceftriaxone owing to high documented resistance
rates. This recommendation includes Rio de Janeiro and is based on small studies because
Brazil lacks a surveillance programme for gonococcal resistance [<xref rid="R5" ref-type="bibr">5</xref>].</p><p id="P3">Based on the importance of ESC resistance surveillance in <italic>N.
gonorrhoeae</italic> worldwide, this retrospective study aimed to investigate the
occurrence of Cef<sup>RS</sup> strains in Rio de Janeiro, which may represent a
high-risk phenotype that might spread within the population following the introduction
of ceftriaxone.</p><p id="P4"><italic>Neisseria gonorrhoeae</italic> isolates obtained from patients with acute
gonorrhoea were sent to the Laboratory for Investigation in Medical Microbiology (LIMM,
Brazil) by public and private healthcare facilities in Rio de Janeiro between 2006 and
2015. A total of 116 isolates were included in the study without screening, and isolate
identification was confirmed using matrix-assisted laser desorption/ionisation
time-of-flight (MALDI-TOF) (Bruker Biotyper 3.1; Bruker Daltonics, Billerica, MA).
Patient data included specimen type, sex and age. Ceftriaxone, cefixime, penicillin,
tetracycline and ciprofloxacin MICs were determined by agar dilution according to CLSI
guidelines, and azithromycin MICs were determined by Etest (bioM&#x000e9;rieux, Rio de
Janeiro, Brazil). Cef<sup>RS</sup> isolates were characterised according to associated
resistance mechanisms and whole-genome sequence (WGS)-based strain typing.</p><p id="P5">WGS was conducted using Illumina HiSeq and MiSeq platforms (Illumina Inc., San
Diego, CA). The obtained data were assembled using CLC Genomics Workbench 7 (<ext-link ext-link-type="uri" xlink:href="https://www.qiagenbioinformatics.com/products/clc-genomics-workbench/">https://www.qiagenbioinformatics.com/products/clc-genomics-workbench/</ext-link>),
and the software was also used to investigate mutations associated with resistance to
cefixime <italic>(penA)</italic>,penicillin <italic>(ponA, porB</italic> and
<italic>rps)</italic>, tetracycline <italic>(porB</italic> and S10 ribosomal
protein) and fluoroquinolones <italic>(gyrA</italic> and <italic>parC)</italic> by
aligning the translated proteins with reference sequences. Moreover, CLC Genomics
Workbench 7 was also used to extract gene sequences for multilocus sequence typing
(MLST) (<ext-link ext-link-type="uri" xlink:href="https://pubmlst.org/neisseria/">https://pubmlst.org/neisseria/</ext-link>) and to identify
plasmids conferring resistance to penicillin (Asia, Africa and Toronto/Rio) and
tetracycline (Dutch and American) via the in silico alignment of primer sequences
targeting these plasmids.</p><p id="P6">Of the 116 <italic>N. gonorrhoeae</italic> isolates, 7 (6.0%) exhibited
Cef<sup>RS</sup>, however reduced susceptibility to ceftriaxone was not detected.
These isolates were collected between 2010 and 2015 from male and female patients
ranging in age from 24 to 59 years. Six of the Cef<sup>RS</sup> isolates encoded the
mosaic <italic>penA</italic> XXXIV allele and one encoded the <italic>penA</italic> XII
allele. All seven isolates were resistant to penicillin, tetracycline and ciprofloxacin,
and these patterns were associated with chromosomal mutations in <italic>ponA, porB,
rpsJ, gyrA</italic> and <italic>parC</italic> (detected in six isolates) or with the
combination of a Toronto/Rio &#x003b2;-lactamase plasmid, a <italic>tetM</italic>
American plasmid, and <italic>gyrA</italic> and <italic>parC</italic> mutations
(detected in one isolate). Moreover, two Cef<sup>RS</sup> isolates exhibited
azithromycin MICs of &#x0003e;2 mg/L (<xref rid="T1" ref-type="table">Table 1</xref>).
The seven Cef<sup>RS</sup> isolates were assigned to ST1901, which is a sequence type
associated with increased ESC resistance in North America, Asia and Europe that also
contains the mosaic <italic>penA</italic> XXXIV allele [<xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R3" ref-type="bibr">3</xref>].</p><p id="P7">A limitation of this study is the type of collection investigated, which is
unsuitable for prevalence estimations. Nevertheless, we determined that
multidrug-resistant CefRS <italic>N. gonorrhoeae</italic> have been isolated in Rio de
Janeiro since 2010, including two isolates exhibiting azithromycin resistance. Although
no outbreaks related to similar strains have been described in Brazil, these results
highlight the presence of highly relevant resistance phenotypes, which might pose a
significant threat to the treatment of gonorrhoea in Rio de Janeiro.</p></body><back><ack id="S2"><title>Acknowledgments</title><p id="P8">This work was presented in part at the 11th Sequencing, Finishing, and
Analysis in the Future Meeting, 1-3 June 2016, Santa Fe, NM. The abstracts
&#x02018;Genomic sequencing and analysis of <italic>Neisseria gonorrhoeae</italic>
clinical isolates to characterize antimicrobial resistance in Rio de Janeiro,
Brazil&#x02019; and &#x02018;Detection and characterization of Brazilian gonococcal
clinical isolates with reduced susceptibility to cephalosporin antibiotics&#x02019;
are available at <ext-link ext-link-type="uri" xlink:href="http://www.lanl.gov/conferences/sequencing-finishing-analysis-future/index.php">http://www.lanl.gov/conferences/sequencing-finishing-analysis-future/index.php</ext-link>.
The conclusions, findings and opinions expressed by the authors do not necessarily
reflect the official position of the US Centers for Disease Control and Prevention
(CDC).</p><p id="P9"><italic>Funding</italic>: This study was supported by the Brazilian funding
agencies CAPES (Coordination for the Improvement of Higher Education Personnel),
CNPq (National Council for Scientific and Technological Development) and FAPERJ
(Research Support Foundation of the State of Rio de Janeiro), and partially by the
CDC, with additional support from the project AMD-18.</p></ack><fn-group><fn fn-type="COI-statement" id="FN1"><p id="P10"><italic>Competing interests</italic>: None declared.</p></fn><fn id="FN2"><p id="P11"><italic>Ethical approval</italic>: Not required.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><name><surname>Unemo</surname><given-names>M</given-names></name>, <name><surname>Shafer</surname><given-names>WM</given-names></name>. <article-title>Future treatment of gonorrhea&#x02014;novel emerging
drugs are essential and in progress?</article-title>
<source>Expert Opin Emerg Drugs</source>
<year>2015</year>;<volume>20</volume>:<fpage>357</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">25907334</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><name><surname>Unemo</surname><given-names>M</given-names></name>, <name><surname>Golparian</surname><given-names>D</given-names></name>, <name><surname>Nicholas</surname><given-names>R</given-names></name>, <name><surname>Ohnishi</surname><given-names>M</given-names></name>, <name><surname>Gallay</surname><given-names>A</given-names></name>, <name><surname>Sednaoui</surname><given-names>P</given-names></name>. <article-title>High-level cefixime- and ceftriaxone-resistant
<italic>Neisseria gonorrhoea</italic> in France: novel
<italic>penA</italic> mosaic allele in a successful international clone
causes treatment failure</article-title>. <source>Antimicrob Agents
Chemother</source>
<year>2012</year>;<volume>56</volume>:<fpage>1273</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">22155830</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><name><surname>Grad</surname><given-names>YH</given-names></name>, <name><surname>Kirkcaldy</surname><given-names>RD</given-names></name>, <name><surname>Trees</surname><given-names>D</given-names></name>, <name><surname>Dordel</surname><given-names>J</given-names></name>, <name><surname>Harris</surname><given-names>SR</given-names></name>, <name><surname>Goldstein</surname><given-names>E</given-names></name>, <etal/>
<article-title>Genomic epidemiology of <italic>Neisseria gonorrhoeae</italic>
with reduced susceptibility to cefixime in the USA: a retrospective
observational study</article-title>. <source>Lancet Infect Dis</source>
<year>2014</year>;<volume>14</volume>:<fpage>220</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">24462211</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><name><surname>Ohnishi</surname><given-names>M</given-names></name>, <name><surname>Golparian</surname><given-names>D</given-names></name>, <name><surname>Shimuta</surname><given-names>K</given-names></name>, <name><surname>Saika</surname><given-names>T</given-names></name>, <name><surname>Hoshina</surname><given-names>S</given-names></name>, <name><surname>Iwasaku</surname><given-names>K</given-names></name>, <etal/>
<article-title>Is <italic>Neisseria gonorrhoeae</italic> initiating a future era
of untreatable gonorrhea?: detailed characterization of the first strain
with high-level resistance to ceftriaxone</article-title>.
<source>Antimicrob Agents Chemother</source>
<year>2011</year>;<volume>55</volume>:<fpage>3538</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">21576437</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="book"><collab>CONITEC</collab>.
<chapter-title>Protocolo Cl&#x000ed;nico e Diretrizes
Terap&#x000ea;uticas</chapter-title>
<source>Infec&#x000e7;&#x000f5;es
Sexualmente Transmiss&#x000ed;veis</source>, <year>2015</year>
<publisher-loc>Bras&#x000ed;lia, DF, Brazil</publisher-loc>:
<publisher-name>Ministerio da Saude</publisher-name>
<comment><ext-link ext-link-type="uri" xlink:href="http://conitec.gov.br/images/Relatorios/2015/Relatorio_PCDT-IST_final.pdf">http://conitec.gov.br/images/Relatorios/2015/Relatorio_PCDT-IST_final.pdf</ext-link>.
[Accessed</comment>
<date-in-citation>10 June 2016</date-in-citation>].</mixed-citation></ref></ref-list></back><floats-group><table-wrap id="T1" position="float" orientation="landscape"><label>Table 1</label><caption><p id="P12">Characteristics of seven <italic>Neisseria gonorrhoeae</italic> isolates
assigned to ST1901 by multilocus sequence typing (MLST) with reduced
susceptibility to cefixime from Rio de Janeiro, Brazil.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Year</th><th align="left" valign="top" rowspan="1" colspan="1">Specimen type</th><th align="left" valign="top" rowspan="1" colspan="1">Sex</th><th align="left" valign="top" rowspan="1" colspan="1">Age (years)</th><th colspan="6" align="left" valign="top" rowspan="1">MIC (mg/L)<sup><xref rid="TFN2" ref-type="table-fn">a</xref></sup></th><th align="left" valign="top" rowspan="1" colspan="1">Resistance profile<sup><xref rid="TFN3" ref-type="table-fn">b</xref></sup></th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" style="border-top: 1px solid" rowspan="1" colspan="1">CEF</th><th align="left" valign="top" style="border-top: 1px solid" rowspan="1" colspan="1">CRO</th><th align="left" valign="top" style="border-top: 1px solid" rowspan="1" colspan="1">PEN</th><th align="left" valign="top" style="border-top: 1px solid" rowspan="1" colspan="1">TET</th><th align="left" valign="top" style="border-top: 1px solid" rowspan="1" colspan="1">CIP</th><th align="left" valign="top" style="border-top: 1px solid" rowspan="1" colspan="1">AZM</th><th align="left" valign="top" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">2010</td><td align="left" valign="top" rowspan="1" colspan="1">Vaginal</td><td align="left" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">32</td><td align="left" valign="top" rowspan="1" colspan="1">0.25</td><td align="left" valign="top" rowspan="1" colspan="1">0.03</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">0.5</td><td align="left" valign="top" rowspan="1" colspan="1">CMRP/CMRT/CRNG</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2011</td><td align="left" valign="top" rowspan="1" colspan="1">Urine</td><td align="left" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">0.25</td><td align="left" valign="top" rowspan="1" colspan="1">0.06</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1">0.25</td><td align="left" valign="top" rowspan="1" colspan="1">CMRP/CMRT/CRNG</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2013</td><td align="left" valign="top" rowspan="1" colspan="1">Urine</td><td align="left" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">24</td><td align="left" valign="top" rowspan="1" colspan="1">0.25</td><td align="left" valign="top" rowspan="1" colspan="1">0.06</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">0.38</td><td align="left" valign="top" rowspan="1" colspan="1">CMRP/CMRT/CRNG</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2013</td><td align="left" valign="top" rowspan="1" colspan="1">Urethral</td><td align="left" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">54</td><td align="left" valign="top" rowspan="1" colspan="1">0.25</td><td align="left" valign="top" rowspan="1" colspan="1">0.06</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1">1.5</td><td align="left" valign="top" rowspan="1" colspan="1">PPNG/TRNG/CRNG</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2013</td><td align="left" valign="top" rowspan="1" colspan="1">Cervix</td><td align="left" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">58</td><td align="left" valign="top" rowspan="1" colspan="1">0.25</td><td align="left" valign="top" rowspan="1" colspan="1">0.06</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="left" valign="top" rowspan="1" colspan="1">CMRP/CMRT/CRNG/AZRNG</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2014</td><td align="left" valign="top" rowspan="1" colspan="1">Vaginal</td><td align="left" valign="top" rowspan="1" colspan="1">F</td><td align="left" valign="top" rowspan="1" colspan="1">59</td><td align="left" valign="top" rowspan="1" colspan="1">0.25</td><td align="left" valign="top" rowspan="1" colspan="1">0.06</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">CMRP/CMRT/CRNG/AZRNG</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2015</td><td align="left" valign="top" rowspan="1" colspan="1">Urethral</td><td align="left" valign="top" rowspan="1" colspan="1">M</td><td align="left" valign="top" rowspan="1" colspan="1">49</td><td align="left" valign="top" rowspan="1" colspan="1">0.25</td><td align="left" valign="top" rowspan="1" colspan="1">0.06</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">0.38</td><td align="left" valign="top" rowspan="1" colspan="1">CMRP/CMRT/CRNG</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p id="P13">MIC, minimum inhibitory concentration; CEF, cefixime; CRO,
ceftriaxone; PEN, penicillin; TET, tetracycline; CIP, ciprofloxacin; AZM,
azithromycin; CLSI, Clinical and Laboratory Standard Institute; EUCAST,
European Committee on Antimicrobial Susceptibility Testing; CDC, US Centers
for Disease Control and Prevention.</p></fn><fn id="TFN2"><label>a</label><p id="P14">Resistance breakpoints according to the CLSI/EUCAST are as follows:
CEF, &#x0003e;0.25 */&#x0003e;0.125; CRO, &#x0003e;0.25 */&#x0003e;0.125; PEN,
&#x02265;2/&#x02265;1; TET, &#x02265;2/&#x02265;1; CIP, &#x02265;1/&#x02265;0.5;
and AZM, &#x0003e;0.5 **. * The CLSI does not determine resistance breakpoint
for CEF and CRO; it considers &#x0003c;0.25 mg/L as susceptible. However, the
CDC Gonococcal Isolate Surveillance Project defines MIC &#x02265; 0.25 mg/L
and MIC &#x02265; 0.125 mg/L as alert values for CEF and CRO resistance,
respectively. ** The CLSI does not determine breakpoints for AZM. However,
in the CDC Gonococcal Isolate Surveillance Project, an MIC &#x02265; 2 mg/L
is defined as an alert value for resistance.</p></fn><fn id="TFN3"><label>b</label><p id="P15">CMRP, chromosomally mediated resistance to penicillin; CMRT,
chromosomally mediated resistance to tetracycline; CRNG,
ciprofloxacin-resistant <italic>N. gonorrhoeae</italic>; PPNG,
penicillinase-producing <italic>N. gonorrhoeae</italic>; TRNG,
plasmid-mediated tetracycline resistance; AZRNG, azithromycin-resistant
<italic>N. gonorrhoeae</italic>.</p></fn></table-wrap-foot></table-wrap></floats-group></article>